Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes

Cell Cycle

Volumn 11, Issue 9, 2012, Pages 1804-1817

  Issaenko, Olga A ^a,b   Amerik, Alexander Yu ^c  

^a RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Cancer; Chalcones; Deubiquitinating enzymes; Small molecule inhibitors; Ubiquitin proteasome system

Indexed keywords

AM 146; CARBONYL DERIVATIVE; CHALCONE DERIVATIVE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYSTEINE; POLYUBIQUITIN; PROTEASOME; RA 14; RA 9; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CATALYSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CELL PERMEABILIZATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; NUCLEOPHILICITY; OVARY CANCER; PHENOTYPE; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE; UBIQUITINATION; UTERINE CERVIX CANCER;

EID: 84860755914     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20174     Document Type: Article

References (40)

1. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138:389-403; PMID:19615732; http://dx.doi.org/10.1016/j.cell.2009.04.042.
2. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123:773-86; PMID:16325574; http://dx.doi. org/10.1016/j.cell.2005.11.007.
3. Wilkinson KD. DUB at a glance. J Cell Sci 2009; 122:2325-9; PMID:19571111; http://dx.doi. org/10.1242/jcs.041046.
4. Hussain S, Zhang Y, Galardy PJ. DUB and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle 2009; 8:1688-97; PMID:19448430; http://dx.doi. org/10.4161/cc.8.11.8739.
5. Luise C, Capra M, Donzelli M, Mazzarol G, Jodice MG, Nuciforo P, et al. An atlas of altered expression of deubiquitinating enzymes in human cancer. PLoS One 2011; 6:15891; PMID:21283576; http://dx.doi. org/10.1371/journal.pone. 0015891.
6. Fang Y, Fu D, Shen XZ. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 2010; 1806:1-6; PMID:20302916.
7. Colland F. The therapeutic potential of deubiquitinating enzyme inhibitors. Biochem Soc Trans 2010; 38:137-43; PMID:20074048; http://dx.doi. org/10.1042/BST0380137.
8. Atanassov BS, Koutelou E, Dent SY. The role of deubiquitinating enzymes in chromatin regulation. FEBS Lett 2010; PMID:20974139.
9. Guédat P, Colland F. Patented small-molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 2007; 8:14; PMID:18047738; http://dx.doi. org/10.1186/1471-2091-8-S1-S14.
10. Hybrigenics SA. WO2007017758 (2007).
11. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8:2286-95; PMID:19671755; http://dx.doi. org/10.1158/1535-7163.MCT-09-0097.
12. Novartis AG. WO2007009715 (2007).
13. Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J 2001; 20:5187-96; PMID:11566882; http://dx.doi. org/10.1093/emboj/20.18.5187.
14. Hershko A, Rose IA. Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes. Proc Natl Acad Sci USA 1987; 84:1829-33; PMID:3031653; http://dx.doi.org/10.1073/pnas.84.7.1829.
15. Mullally JE, Moos PJ, Edes K, Fitzpatrick FA. Cyclopentenone prostaglandins of the J series inhibit the ubiquitin isopeptidase activity of the proteasome pathway. J Biol Chem 2001; 276:30366-73; PMID:11390388; http://dx.doi.org/10.1074/jbc. M102198200.
16. Mullally JE, Fitzpatrick FA. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharmacol 2002; 62:351-8; PMID:12130688; http://dx.doi. org/10.1124/mol.62.2.351.
17. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010; 70:9265-76; PMID:21045142; http://dx.doi. org/10.1158/0008-5472.CAN-10-1530.
18. Bazzaro M, Anchoori RK, Mudiam MK, Issaenko O, Kumar S, Karanam B, et al. α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 2011; 54:449-56; PMID:21186794; http://dx.doi.org/10.1021/ jm100589p.
19. Achanta G, Modzelewska A, Feng L, Khan SR, Huang P. A boronic-chalcone derivative exhibits potent anti-cancer activity through inhibition of the proteasome. Mol Pharmacol 2006; 70:426-33; PMID:16636137.
20. Amerik AYu, Swaminathan S, Krantz BA, Wilkinson KD, Hochstrasser M. In vivo disassembly of free polyubiquitin chains by yeast Ubp14 modulates rates of protein degradation by the proteasome. EMBO J 1997; 16:4826-38; PMID:9305625; http://dx.doi. org/10.1093/emboj/16.16.4826.
21. Luker GD, Pica CM, Song J, Luker KE, Piwnica- Worms D. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 2003; 9:969-73; PMID:12819780; http://dx.doi.org/10.1038/nm894.
22. Stack JH, Whitney M, Rodems SM, Pollok BA. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 2000; 18:1298-302; PMID:11101811; http://dx.doi. org/10.1038/82422.
23. Papa FR, Hochstrasser M. The yeast DOA4 gene encodes a deubiquitinating enzyme related to a product of the human tre-2 oncogene. Nature 1993; 366:313-9; PMID:8247125; http://dx.doi. org/10.1038/366313a0.
24. Li T, Naqvi NI, Yang H, Teo TS. Identification of a 26S proteasome-associated UCH in fission yeast. Biochem Biophys Res Commun 2000; 272:270- 5; PMID:10872838; http://dx.doi.org/10.1006/ bbrc.2000.2767.
25. Li Z, Melandri F, Berdo I, Jansen M, Hunter L, Wright S, et al. Delta12-Prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochem Biophys Res Commun 2004; 319:1171-80; PMID:15194490; http://dx.doi.org/10.1016/j. bbrc.2004.05.098.
26. Dayal S, Sparks A, Jacob J, Allende-Vega N, Lane DP, Saville MK. Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem 2009; 284:5030-41; PMID:19098288; http://dx.doi. org/10.1074/jbc.M805871200.
27. Westermarck J. Regulation of transcription factor function by targeted protein degradation: an overview focusing on p53, c-Myc and c-Jun. Methods Mol Biol 2010; 647:31-6; PMID:20694659; http://dx.doi. org/10.1007/978-1-60761-738- 9-2.
28. Shan J, Zhao W, Gu W. Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell 2009; 36:469-76; PMID:19917254; http://dx.doi. org/10.1016/j.molcel.2009.10.018.
29. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29:405-34; PMID:20737283; http://dx.doi.org/10.1007/s10555-010-9235-2.
30. Yang H, Landis-Piwowar KR, Chen D, Milacic V, Dou QP. Natural compounds with proteasome inhibitory activity for cancer prevention and treatment. Curr Protein Pept Sci 2008; 9:227-39; PMID:18537678; http://dx.doi.org/10.2174/ 138920308784533998.
31. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008; 68:7283-92; PMID:18794115; http://dx.doi.org/10. 1158/0008-5472.CAN-07-6246.
32. Dikshit P, Goswami A, Mishra A, Chatterjee M, Jana NR. Curcumin induces stress response, neurite outgrowth and prevent NFkappaB activation by inhibiting the proteasome function. Neurotox Res 2006; 9:29-37; PMID:16464750; http://dx.doi.org/10.1007/ BF03033305.
33. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? AAPS J 2009; 11:495-510; PMID:19590964; http://dx.doi.org/10.1208/s12248-009-9128-x.
34. Si X, Wang Y, Wong J, Zhang J, McManus BM, Luo H. Dysregulation of the ubiquitin-proteasome system by curcumin suppresses coxsackievirus B3 replication. J Virol 2007; 81:3142-50; PMID:17229707; http:// dx.doi.org/10.1128/JVI.02028-06.
35. Straus DS, Glass CK. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 2001; 21:185-210; PMID:11301410; http://dx.doi.org/10.1002/med.1006.
36. Yadav VR, Prasad S, Sung B, Aggarwal BB. The role of chalcones in suppression of NFκB-mediated inflammation and cancer. Int Immunopharmacol 2011; 11:295- 309; PMID:21184860; http://dx.doi.org/10.1016/j. intimp.2010.12.006.
37. Becker K, Marchenko ND, Palacios G, Moll UM. A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle 2008; 7:1205- 13; PMID:18418047; http://dx.doi.org/10.4161/ cc.7.9.5756.
38. Kip1. Mol Cell Biol 2009; 29:547- 58; PMID:19015242; http://dx.doi.org/10.1128/ MCB.00329-08.
39. 1-S progression. Cancer Res 2010; 70:3329-39; PMID:20388806; http://dx.doi.org/10.1158/0008-5472.CAN-09- 4152.
40. Li S, Sonenberg N, Gingras AC, Peterson M, Avdulov S, Polunovsky VA, et al. Translational control of cell fate: availability of phosphorylation sites on translational repressor 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002; 22:2853-61; PMID:11909977; http://dx.doi.org/10.1128/MCB.22.8.2853-61. 2002.